Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC105P with carboplatin and gemcitabine for partially platinum-sensitive ovarian cancer
ACTRN12612000522819Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of BNC105P in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 arms), sponsored by University of Sydney. Primary endpoints: Recommended dose of BNC105P and Overall response rate. Started Jul 2012; status: completed.
02
Drugs
BNC105P
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ACTRN12612000522819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000522819.